Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.
The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 29, 23 | -0.42 Decreased by -16.67% | -0.38 Decreased by -10.53% |
| Aug 31, 23 | -1.48 Decreased by -92.21% | -0.93 Decreased by -59.14% |
| May 31, 23 | -0.38 Increased by +28.30% | -0.38 |
| Mar 28, 23 | -1.55 Decreased by -229.79% | -0.40 Decreased by -287.50% |
| Nov 30, 22 | -0.36 Decreased by -33.33% | -0.36 |
| Aug 30, 22 | -0.77 Decreased by -28.33% | -0.65 Decreased by -18.46% |
| Jun 1, 22 | -0.53 Increased by +13.11% | -0.53 |
| Mar 31, 22 | -0.47 Increased by +69.68% | -0.67 Increased by +29.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -14.65% | - - |
| Jun 30, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -314.03% | - - |
| Mar 31, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -314.03% | - - |
| Dec 31, 23 | 407.87 K Increased by +N/A% | -7.42 M Decreased by N/A% | Decreased by -1.82 K% - |
| Sep 30, 23 | 407.87 K Decreased by -84.81% | -7.42 M Increased by +54.10% | Decreased by -1.82 K% Decreased by -202.10% |
| Jun 30, 23 | 8.65 M Increased by +120.43% | -2.05 M Increased by +95.69% | Decreased by -23.76% Increased by +98.04% |
| Mar 31, 23 | 8.65 M Increased by +340.86% | -2.05 M Increased by +91.38% | Decreased by -23.76% Increased by +98.04% |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |